The Congenital Heart Disease drugs in development market research report provides comprehensive information on the therapeutics under development for Congenital Heart Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Congenital Heart Disease. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Congenital Heart Disease and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Congenital Heart Disease by seven companies/universities/institutes. The top development phase for Congenital Heart Disease is phase ii with two drugs in that stage. The Congenital Heart Disease pipeline has seven drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Congenital Heart Disease pipeline products market are: Capricor Therapeutics, Mesoblast and Bayer.
The key targets in the Congenital Heart Disease pipeline products market include Coagulation Factor X, and cGMP Specific 3′,5′ Cyclic Phosphodiesterase.
The key mechanisms of action in the Congenital Heart Disease pipeline product include cGMP Specific 3′,5′ Cyclic Phosphodiesterase Inhibitor with one drug in Pre-Registration. The Congenital Heart Disease pipeline products include four routes of administration with the top ROA being Intracardiac and three key molecule types in the Congenital Heart Disease pipeline products market including Cell Therapy, and Small Molecule.
Congenital Heart Disease overview
Congenital heart disease is an impairment of the heart’s structure that is present at birth. It may change the normal flow of blood through the heart. It is the most common type of birth defect, occurring in about 1% of live births in the US. There are different types of congenital heart defects; the most common involve the inside walls of the heart, the valves of the heart, or the large blood vessels that carry blood to and from the heart. Some defects are simple and require no treatment, while others are critical and require treatment soon after birth.
For a complete picture of Congenital Heart Disease’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
